Non-metastatic Castration-resistant Prostate Cancer

• CLINICAL_TRIALS trial_result · 2026-04-14
  Clinical Trial Update: A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

  An observational study of non-metastatic castration-resistant prostate cancer patients who had already decided to be treated with darolutami…

• CLINICAL_TRIALS trial_result · 2025-08-17
  Clinical Trial Update: Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer [Phase 1]

  This ClinicalTrials.gov update reports the completion of a Phase 1 study evaluating relugolix in men with metastatic castration-sensitive an…

• CLINICAL_TRIALS trial_result · 2025-06-08
  Clinical Trial Update: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) [Phase 1, Phase 2]

  This Phase I/II trial of BN-Brachyury Vaccine, M7824, N-803, and Epacadostat in metastatic castration-resistant prostate cancer has complete…

• CLINICAL_TRIALS trial_result · 2025-03-28
  Clinical Trial Update: A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC) [Phase 4]

  Phase 4 trial update for apalutamide in Chinese participants with non-metastatic castration-resistant prostate cancer; results have been pos…

• CLINICAL_TRIALS trial_result · 2018-06-19
  Clinical Trial Update: A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer [Phase 3]

  This Phase 3 clinical trial update reports results for apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2012-06-01
  Clinical Trial Update: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer [Phase 3]

  Phase III trial of ZD4054 (Zibotentan) in non-metastatic hormone-resistant prostate cancer was terminated, with results posted in 2012.